Starpharma (ASX:SPL) has received an upfront payment of US$5.5 million (A$8.5 million) from Genentech, a member of the Roche Group, marking the formal commencement of their recently announced license agreement focused on developing dendrimer-drug conjugates for selected oncology targets. …
Starpharma receives upfront payment from Genentech, launching oncology collaboration
October 23, 2025 Australian Biotech
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News